Mastocytosis. Clinical aspects, diagnostics, therapy

被引:0
|
作者
Lippert, U. [1 ]
机构
[1] Univ Med Gottingen, Klin Dermatol Venerol Allergol, Mastozytosezentorn, Robert Koch Str 40, D-37075 Gottingen, Germany
来源
HAUTARZT | 2017年 / 68卷 / 01期
关键词
WHO classification; Mast cell activation syndrome; Osteoporosis; Anaphylaxis; Tryptase; CHILDHOOD-ONSET MASTOCYTOSIS; SYSTEMIC MASTOCYTOSIS; UPDATE; ADULTS;
D O I
10.1007/s00105-016-3911-2
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Mastocytosis is a rare, almost exclusively sporadically occurring disease involving an increase in clonal tissue mast cells. The disease spectrum is heterogenous, ranging from isolated skin lesions with a normal life expectancy to rare, aggressive forms with very poor prognosis. Children are often affected. But whereas these almost invariantly display solely a cutaneous mastocytosis with polymorphous skin lesions, in adults the lesions are small and maculopapular and in over 80% of cases accompanied by involvement of bone marrow and the D816V activating mutation of the gene for the caEuroKit receptor. There are many symptoms for the disease. Patients suffer frequently from pruritus, diarrhea, abdominal cramp, palpitations and flush. Osteoporosis is often present, with osteolysis with pathological fractures frequently involved in more aggressive forms. Patients are especially at risk to severe anaphylaxis caused by hymenoptera stings. Therapy is symptomatic, with cytoreductive therapy reserved for resistant and aggressive forms.
引用
收藏
页码:67 / 75
页数:9
相关论文
共 50 条
  • [1] Systemic mastocytosis.: Classification, symptoms, therapy
    Kraemer, DM
    Grunewald, SM
    Kolb-Mäurer, A
    MEDIZINISCHE KLINIK, 2004, 99 (03) : 131 - 136
  • [2] Mastocytosis. Review of the literature and description of clinical cases
    Melikyan, A. L.
    Subortseva, I. N.
    Goryacheva, S. R.
    Kolosheinova, T. I.
    Vakhrusheva, M. V.
    Kovrigina, A. M.
    Sudarikov, A. B.
    Dvirnyk, V. N.
    Obukhova, T. N.
    TERAPEVTICHESKII ARKHIV, 2014, 86 (12) : 127 - 134
  • [3] Smoldering systemic mastocytosis. Successful therapy with cladribine
    Schleyer, V
    Meyer, S
    Landthaler, M
    Szeimies, RM
    HAUTARZT, 2004, 55 (07): : 658 - 662
  • [4] Dasatinib (Sprycel™) therapy for patients with systemic mastocytosis.
    Verstovsek, Srdan
    Kantarjian, Hagop
    Cortes, Jorge
    Ravandi-Kashani, Farhard
    Borthakur, Gautam
    Nicaise, Claude
    Sams, Inga
    Giles, Francis
    Tefferi, Ayalew
    BLOOD, 2006, 108 (11) : 1036A - 1036A
  • [5] Mastocytosis. A challenge in anaesthesiology
    Konrad, F. M.
    Unertl, K. E.
    Schroeder, T. H.
    ANAESTHESIST, 2009, 58 (12): : 1239 - 1243
  • [6] Denileukin diftitox (Ontak™) therapy for patients with systemic mastocytosis.
    Quintas-Cardama, Alfonso
    Kantarjian, Hagop
    Giles, Francis
    Cortes, Jorge
    Verstovsek, Srdan
    BLOOD, 2006, 108 (11) : 306B - 306B
  • [7] α-interferon and systemic mastocytosis.: Therapy results in six cases
    Castellano, PG
    Garcia-Erce, JA
    Alegret, RA
    Rubio, AA
    Artal, PM
    Camara, PV
    Rubio-Felix, D
    Raichs, MG
    REVISTA CLINICA ESPANOLA, 1998, 198 (06): : 345 - 350
  • [8] Inguinal pigmented papules -: Mastocytosis.
    Musette, P
    Descamps, V
    Dupuis, F
    Blanchet, P
    Marinho, E
    Crickx, B
    Belaïch, S
    ARCHIVES OF DERMATOLOGY, 1999, 135 (02) : 205 - +
  • [9] Hymenoptera allergy and systemic mastocytosis.
    Keeton, R. W.
    Akin, C.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2007, 98 (01) : A50 - A50
  • [10] A RARE CASE OF INDOLENT SYSTEMIC MASTOCYTOSIS.
    Brown, T.
    Johnson, K.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2011, 107 (05) : A52 - A52